Skip to search formSkip to main contentSkip to account menu

atorvastatin

Known as: (betaR,deltaR)-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid, (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-pyrrole-1-heptanoic Acid 
A synthetic lipid-lowering agent. Atorvastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, the enzyme which… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2006
Highly Cited
2006
BACKGROUND Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they… 
Highly Cited
2005
Highly Cited
2005
CONTEXT Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied… 
Highly Cited
2005
Highly Cited
2005
Highly Cited
2005
Highly Cited
2005
Review
2003
Review
2003
Hypercholesterolaemia is a risk factor for the development of atherosclerotic disease. Atorvastatin lowers plasma low-density… 
Highly Cited
2002
Highly Cited
2002
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which are approved for cholesterol reduction, may… 
Highly Cited
2002
Highly Cited
2002
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may exert direct effects on vascular cells and beneficially… 
Highly Cited
2001
Highly Cited
2001
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study : A randomized…